Suppression of EZH2 prevents the shift of osteoporotic MSC fate to adipocyte and enhances bone formation during osteoporosis

Molecular Therapy

Volumn 24, Issue 2, 2016, Pages 217-229

  Jing, Huan ^a   Liao, Li ^a   An, Yulin ^a,b   Su, Xiaoxia ^c   Liu, Shiyu ^a   Shuai, Yi ^a   Zhang, Xinjing ^d   Jin, Yan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Zhenjiang Entry Exit Inspection and Quarantine Bureau   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; BETA CATENIN; HISTONE H3; MESSENGER RNA; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR EZH2; TRIMETHYLATED HISTONE H3 LYSINE 27; UNCLASSIFIED DRUG; WNT PROTEIN; WNT1 PROTEIN; WNT10A PROTEIN; WNT6 PROTEIN; EZH2 PROTEIN, MOUSE; HISTONE; POLYCOMB REPRESSIVE COMPLEX 2;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL FATE; CELL LINEAGE; CONTROLLED STUDY; DRUG MECHANISM; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HISTONE METHYLATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; OVARIECTOMY-INDUCED OSTEOPOROSIS; PATHOGENESIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; UPREGULATION; WNT GENE; WNT SIGNALING PATHWAY; ANIMAL; BONE DEVELOPMENT; CELL DIFFERENTIATION; CYTOLOGY; DISEASE MODEL; DNA METHYLATION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY;

ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DNA METHYLATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; FEMALE; GENE KNOCKDOWN TECHNIQUES; HISTONES; MESENCHYMAL STROMAL CELLS; MICE; OSTEOGENESIS; OSTEOPOROSIS; POLYCOMB REPRESSIVE COMPLEX 2; WNT PROTEINS;

EID: 84959534327     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.152     Document Type: Article

References (48)

1. A2001. NIH consensus development panel on osteoporosis prevention, diagnosis and therapy. JAMA 85: 785-795.
2. Bergman, RJ, Gazit, D, Kahn, AJ, Gruber, H, McDougall, S and Hahn, TJ (1996). Age-related changes in osteogenic stem cells in mice. J Bone Miner Res 11: 568-577.
3. D'Ippolito, G, Schiller, PC, Ricordi, C, Roos, BA and Howard, GA (1999). Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res 14: 1115-1122.
4. Bianco, P, Robey, PG and Simmons, PJ (2008). Mesenchymal stem cells: revisiting history, concepts and assays. Cell Stem Cell 2: 313-319.
5. Caplan, AI (2007). Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213: 341-347.
6. Justesen, J, Stenderup, K, Ebbesen, EN, Mosekilde, L, Steiniche, T and Kassem, M (2001). Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2: 165-171.
7. Kassem, M and Marie, PJ (2011). Senescence-Associated intrinsic mechanisms of osteoblast dysfunctions. Aging Cell 10: 191-197.
8. Nishikawa, K, Nakashima, T, Takeda, S, Isogai, M, Hamada, M, Kimura, A, et al. (2010). Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J Clin Invest 120: 3455-3465.
9. Takada, I, Kouzmenko, AP, Kato, S (2009). Wnt and PPARsignaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 5: 442-447.
10. Bennett, CN, Longo, KA, Wright, WS, Suva, LJ, Lane, TF, Hankenson, KD, et al. (2005). Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 102: 3324-3329.
11. Manolagas, SC and Almeida, M (2007). Gone with the Wnts: β-catenin, T-cell factor, forkhead box O and oxidative stress in age-Dependent diseases of bone, lipid and glucose metabolism. Mol Endocrinol 21: 2605-2614.
12. Ye, L, Fan, Z, Yu, B, Chang, J, Al Hezaimi, K, Zhou, X, et al. (2012). Histone demethylases KDM4B and KDM6B promote osteogenic differentiation of human MSCs. Cell Stem Cell 11: 50-61.
13. Ge, W, Liu, Y, Chen, T, Zhang, X, Lv, L, Jin, C, et al. (2014). The epigenetic promotion of osteogenic differentiation of human adipose-Derived stem cells by the genetic and chemical blockade of histone demethylase LSD1. Biomaterials 35: 6015-6025.
14. Jenuwein, T and Allis, CD (2001). Translating the histone code. Science 293: 1074-1080.
15. Shi, Y (2007). Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet 8: 829-833.
16. Agger, K, Christensen, J, Cloos, PA and Helin, K (2008). The emerging functions of histone demethylases. Curr Opin Genet Dev 18: 159-168.
17. Zhu, J, Adli, M, Zou, JY, Verstappen, G, Coyne, M, Zhang, X, et al. (2013). Genomewide chromatin state transitions associated with developmental and environmental cues. Cell 152: 642-654.
18. Wang, L, Jin, Q, Lee, JE, Su, IH and Ge, K (2010). Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc Natl Acad Sci USA 107: 7317-7322.
19. Boyer, LA, Plath, K, Zeitlinger, J, Brambrink, T, Medeiros, LA, Lee, TI, et al. (2006). Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441: 349-353.
20. Bernstein, BE, Mikkelsen, TS, Xie, X, Kamal, M, Huebert, DJ, Cuff, J, et al. (2006). A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125: 315-326.
21. Bernstein, BE, Meissner, A and Lander, ES (2007). The mammalian epigenome. Cell 128: 669-681.
22. Ezhkova, E, Pasolli, HA, Parker, JS, Stokes, N, Su, IH, Hannon, G, et al. (2009). Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 136: 1122-1135.
23. Caretti, G, Di Padova, M, Micales, B, Lyons, GE and Sartorelli, V (2004). The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Gene & Dev 18: 2627-2638.
24. Hemming, S, Cakouros, D, Isenmann, S, Cooper, L, Menicanin, D, Zannettino, A, et al. (2014). EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. Stem Cells 32: 802-815.
25. Wei, Y, Chen, YH, Li, LY, Lang, J, Yeh, SP, Shi, B, et al. (2011). CDK1-Dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol 13: 87-94.
26. Liao, L, Yang, X, Su, X, Hu, C, Zhu, X, Yang, N, et al. (2013). Redundant miR-3077-5p and miR-705 mediate the shift of mesenchymal stem cell lineage commitment to adipocyte in osteoporosis bone marrow. Cell Death Dis 4: e600.
27. Buchschacher, GL, Jr, Wong-Staal, F (2000). Development of lentiviral vectors for gene therapy for human diseases. Blood 95: 2499-2504.
28. Zhou, J, Bi, C, Cheong, LL, Mahara, S, Liu, SC, Tay, KG, et al. (2011). The histone methyltransferase inhibitor DZNep upregulates TXNIP, increases ROS production and targets leukemia cells in AML. Blood 118: 2830-2839.
29. Fiskus, W, Wang, Y, Sreekumar, A, Buckley, KM and Shi, H (2009). Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-Deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114: 2733-2743.
30. Tan, J, Yang, X, Zhuang, L, Jiang, X, Chen, W, Lee, PL, et al. (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050-1063.
31. Gordon, RK, Ginalski, K, Rudnicki, WR, Rychlewski, L, Pankaskie, MC, Bujnicki, JM, et al. (2003). Anti-HIV-1 activity of 3-Deaza-Adenosine analogs inhibition of S-Adenosylhomocysteine hydrolase and nucleotide congeners. Eur J Biochem 270: 3507-3517.
32. Mayers, DL, Mikovits, JA, Joshi, B, Hewlett, IK, Estrada, JS, Wolfe, AD, et al. (1995). Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-Deazaadenosine analogs: increased potency against 3'-Azido-3'-Deoxythymidine-resistant HIV-1 strains. Proc Natl Acad Sci USA 92: 215-219.
33. Krishnan, V, Bryant, HU and Macdougald, OA (2006). Regulation of bone mass by Wnt signaling. J Clin Invest 116: 1202-1209.
34. Baron, R, Rawadi, G and Roman-Roman, S (2006). Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol 76: 103-127.
35. Takada, I, Kouzmenko, AP and Kato, S (2009). Wnt and PPAR.signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 5: 442-447.
36. Rakyan, VK, Down, TA, Balding, DJ and Beck, S (2011). Epigenome-wide association studies for common human diseases. Nat Rev Genet 12: 529-541.
37. Mill, J and Heijmans, BT (2013). From promises to practical strategies in epigenetic epidemiology. Nat Rev Genet 14: 585-594.
38. Feinberg, AP and Vogelstein, B (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89-92.
39. Urdinguio, RG, Sanchez-Mut, JV and Esteller, M (2009). Epigenetic mechanisms in neurological diseases: genes, syndromes and therapies. Lancet Neurol 8: 1056-1072.
40. Fraga, MF, Ballestar, E, Villar-Garea, A, Boix-Chornet, M, Espada, J, Schotta, G, et al. (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400.
41. Shen, X, Liu, Y, Hsu, YJ, Fujiwara, Y, Kim, J, Mao, X, et al. (2008). EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 32: 491-502.
42. Sher, F, Rossler, R, Brouwer, N, Balasubramaniyan, V, Boddeke, E and Copray, S (2008). Differentiation of neural stem cells into oligodendrocytes: involvement of the polycomb group protein Ezh2. Stem Cells 26: 2875-2883.
43. Bardot, ES, Valdes, VJ, Zhang, J, Perdigoto, CN, Nicolis, S, Hearn, SA, et al. (2013). Polycomb subunits Ezh1 and Ezh2 regulate the Merkel cell differentiation program in skin stem cells. EMBO J 32: 1990-2000.
44. Rando, TA and Chang, HY (2012). Aging, rejuvenation and epigenetic reprogramming: resetting the aging clock. Cell 148: 46-57.
45. Liu, W, Qi, M, Konermann, A, Zhang, L, Jin, F and Jin, Y (2015). The p53/miR-17/ Smurf1 pathway mediates skeletal deformities in an age-related model via inhibiting the function of mesenchymal stem cells. Aging 7: 205-218.
46. Song, L, Liu, M, Ono, N, Bringhurst, FR, Kronenberg, HM and Guo, J (2012). Loss of wnt/β-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes. J Bone Miner Res 27: 2344-2358.
47. Li, CJ, Cheng, P, Liang, MK, Chen, YS, Lu, Q, Wang, JY, et al. (2015). MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J Clin Invest 125: 1509-1522.
48. Wang, W, Li, C, Pang, L, Shi, C, Guo, F, Chen, A, et al. (2014). Mesenchymal stem cells recruited by active TGFs contribute to osteogenic vascular calcification. Stem Cells Dev 23: 1392-1404.